Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer ...

Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are ...

Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.